Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Company profile
Website
CEO
Ankit A. Mahadevia
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
134100476
Latest filings (excl ownership)
15-12B
Securities registration termination
30 Dec 15
25-NSE
Exchange delisting
22 Dec 15
8-K
Other Events
17 Dec 15
DEF 14A
Definitive proxy
17 Nov 15
PRE 14A
Preliminary proxy
6 Nov 15
10-Q
2015 Q3
Quarterly report
5 Nov 15
8-K
Kaplan to Acquire SmartPros
23 Oct 15
10-Q
2015 Q2
Quarterly report
6 Aug 15
8-K
Submission of Matters to a Vote of Security Holders
26 Jun 15
10-Q
2015 Q1
Quarterly report
5 May 15
Institutional ownership, Q3 2021
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 76.00 k |
Total shares | 4.15 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Patriot Financial Group Insurance Agency | 4.15 k | $76.00 k |